

EEA MiFID II product governance / Retail investors, professional investors and ECPs target market – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Securities, taking into account the five (5) categories referred to in item 18 of the Guidelines published by the European Securities and Markets Authority (**ESMA**) on 5 February 2018, has led to the conclusion that the target market for the Securities is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU (as amended, **MiFID II**). Any person subsequently offering, selling or recommending the Securities (a **Distributor**) should take into consideration the manufacturer's target market assessment; however, a Distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Securities (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels.

UK MiFIR II product governance / Retail investors, professional investors and ECPs target market – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Securities has led to the conclusion that the target market for the Securities is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook (**COBS**), and professional clients, as defined in Regulation (EU) No 600/2014, as it forms part of domestic law by virtue of the **European Union (Withdrawal) Act 2018 (EUWA) (UK MiFIR)**, and retail clients, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of EUWA. Any person subsequently offering, selling or recommending the Securities (a **Distributor**) should take into consideration the manufacturer's target market assessment; however, a Distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the **UK MiFIR Product Governance Rules**) is responsible for undertaking its own target market assessment in respect of the Securities (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels.

PRIIPs Regulation – PROHIBITION OF SALES TO EEA RETAIL INVESTORS WITHOUT KID – The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (**EEA**) without an updated key information document required by Regulation (EU) No 1286/2014 (as amended, the **PRIIPs Regulation**) for offering or selling the Securities or otherwise making them available to retail investors in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of MiFID II; (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129, as amended (the **Prospectus Regulation**).

UK PRIIPs Regulation – PROHIBITION OF SALES TO UK RETAIL INVESTORS WITHOUT KID – The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom (**UK**) without an updated key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (**EUWA**) (as amended, the **UK PRIIPs Regulation**) for offering or selling the Securities or otherwise making them available to retail investors in the UK. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (**EUWA**); (ii) a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA (the **UK Prospectus Regulation**).

FINAL TERMS DATED 24 MAY 2022

Issue of up to SEK 100,000,000 Share Linked Redemption Notes due July 2027

under the €50,000,000,000 Structured Debt Instruments Issuance Programme

by
CRÉDIT AGRICOLE CIB FINANCIAL SOLUTIONS
Legal entity identifier (LEI): 969500HUHIE5GG515X42

guaranteed by CRÉDIT AGRICOLE CORPORATE AND INVESTMENT BANK

PART A – CONTRACTUAL TERMS

This document constitutes the Final Terms of the Securities described herein for the purposes of the Prospectus Regulation and must be read in conjunction with the Base Prospectus dated 10 May 2022 which constitutes a base prospectus for the purposes of the Prospectus Regulation (the **Base Prospectus**) in order to obtain all the relevant information. A summary of the issue of the Securities is annexed to these Final Terms. The Base Prospectus and the supplements to the Base Prospectus are available for viewing on the Luxembourg Stock Exchange website (www.bourse.lu) and during normal business hours at the registered office of Crédit Agricole CIB and on its website (<https://www.documentation.ca-cib.com/IssuanceProgram>).

1	(a) Series Number:	6697
	(b) Type of Securities:	Notes
	(c) Tranche Number:	1
	(d) Date on which the Securities become fungible:	Not Applicable
2	Specified Currency	Swedish Kronor (SEK)
3	Aggregate Nominal Amount:	
	(a) Series:	Up to SEK 100,000,000
	(b) Tranche:	Up to SEK 100,000,000
4	Issue Price:	100 % of the Aggregate Nominal Amount.
5	(a) Specified Denominations:	SEK 10,000 Calculation of Redemption based on the Specified Denomination: Applicable
	(b) Minimum Trading Size:	Not Applicable
	(c) Calculation Amount:	SEK 10,000
6	(a) Issue Date:	27 July 2022
	(b) Trade Date(s):	6 July 2022
	(c) Interest Commencement Date:	Not Applicable
7	Redemption Date:	22 July 2027, subject to any early redemption date
8	Type of Securities:	
	(a) Interest:	Not Applicable

(b)	Redemption:	Share Linked Redemption Security (Further particulars specified below in "PROVISIONS RELATING TO REDEMPTION")
(c)	U.S. Securities:	Not Applicable
(d)	Other:	Swedish Securities (Further particulars specified below in "OPERATIONAL INFORMATION")
(e)	Additional U.S. Regulatory Disclosure:	Not Applicable
(f)	Partly Paid Securities Provisions:	Not Applicable
9	Date Board approval for issuance of Securities obtained:	Authorisation given by the Board of Directors of Crédit Agricole CIB Financial Solutions dated 11 June 2021.
10	Method of distribution:	Non-syndicated
11	Asset Conditions:	Share Linked Asset Conditions applicable in accordance with Annex 1
12	Alternative Currency Conditions:	Not Applicable
PROVISIONS RELATING TO INTEREST (IF ANY) PAYABLE		
13	Floating Rate Security:	Not Applicable
14	Linked Interest Security:	Not Applicable
	(a) Universal Leverage:	Not Applicable
	(b) Universal Margin:	Not Applicable
15	Zero Coupon Security:	Not Applicable
PAYOFF FEATURES (IF ANY) RELATING TO INTEREST		
16	Payoff Features:	Not Applicable
PROVISIONS RELATING TO REDEMPTION		
17	Redemption Determination Date(s):	For the purposes of determining the Final Redemption Amount, the Redemption Observation Date (see also paragraph 19(b) of these Final Terms) For the purposes of determining an Early Redemption Amount, the Early Redemption Observation Date on which the Early Redemption Trigger Event occurs (see also paragraph 19(a) of these Final Terms)
18	Redemption Method:	Standard Redemption in accordance with Annex 9, Paragraph 2 The Early Redemption Amount will be equal to: <i>Reference Price x Nominal Amount</i> as determined by the Calculation Agent on the
	(a) Early Redemption Amount for the purposes of General Condition 6.2 (<i>Early Redemption Trigger Events</i>) determined in accordance with:	

Redemption Determination Date

- i. Redemption Payoff: Not Applicable
- ii. Redemption Unwind Costs: Not Applicable
- iii. Reference Price: In relation to an Early Redemption Observation Date, the corresponding percentage specified in the table below:

t	Early Redemption Observation Date	Early Redemption Date	ERB	Reference Price
1	10/07/2023	24/07/2023	100%	As of the date of these Final Terms, indicatively set at 114.50% but may be a lesser or greater amount, provided that it will not be less than 110.00%
2	08/07/2024	22/07/2024	100%	As of the date of these Final Terms, indicatively set at 129.00% but may be a lesser or greater amount, provided that it will not be less than 120.00%
3	08/07/2025	22/07/2025	100%	As of the date of these Final Terms, indicatively set at 143.50% but may be a lesser or greater amount, provided that it will not be less than 130.00%
4	08/07/2026	22/07/2026	100%	As of the date of these Final Terms, indicatively set at 158.00% but may be a lesser or greater amount, provided that it will not be less than 140.00%

- iv. Early Redemption Trigger Event(s): **Applicable**
Applicable as per Automatic Early Redemption Trigger (Annex 8, Chapter 7)
- Automatic Early Redemption Event: Performance_ER higher than or equal to the relevant ERB on at least one Early Redemption Observation Date
- ERB (**Early Redemption Barrier**): In respect of an Early Redemption Observation Date, the corresponding percentage as specified in the table above
- Early Redemption Date(s): In respect of each Early Redemption Observation Date, the corresponding Early Redemption Date as specified in the table above
- Early Redemption Observation Date(s): Means each Early Redemption Observation Date as specified in the table above
- Early Redemption Observation Period: Not Applicable
- Range: Not Applicable
- Performance_ER: **Worst of Performance**, being the result of the following formula, expressed as a percentage:
$$\text{Min}_i^N \text{ Performance}(i)$$
- Performance(i): With, N means the total number of Underlying(i).
Option 1 applies:

$$\frac{\text{Underlying Value}_i}{\text{Underlying Value}_{i1}}$$

i :	Underlying(i):	Underlying Value _{i1} :	Underlying Value _{i2} :	Weight(i)
1	AstraZeneca PLC (with further information set out in paragraph "INFORMATION ON THE UNDERLYING(S) IF ANY")	Underlying Value on 8 July 2022	Underlying Value on the relevant Early Redemption Observation Date	Not Applicable
2	Novo Nordisk A/S (with further information set out in paragraph "INFORMATION ON THE UNDERLYING(S) IF ANY")	Underlying Value on 8 July 2022	Underlying Value on the relevant Early Redemption Observation Date	Not Applicable
3	Getinge AB (with further information set out in paragraph "INFORMATION ON THE UNDERLYING(S) IF ANY")	Underlying Value on 8 July 2022	Underlying Value on the relevant Early Redemption Observation Date	Not Applicable
4	Pfizer Inc (with further information set out in paragraph "INFORMATION ON THE UNDERLYING(S) IF ANY")	Underlying Value on 8 July 2022	Underlying Value on the relevant Early Redemption Observation Date	Not Applicable

(b) Final Redemption Amount for the purposes of General Condition 6.1 (*Redemption by Instalments and Final Redemption*) determined in accordance with:

Growth Redemption in accordance with Annex 9, Paragraph 4

The Final Redemption Amount will be equal to:

$$(Reference\ Price \times Redemption\ Payoff) \times Nominal\ Amount$$

as determined by the Calculation Agent on the Redemption Determination Date

i. Redemption Payoff:

Determined in accordance with Standard Digital/Performance Redemption (as completed in paragraph "Standard Redemption Payoff Provisions" of these Final Terms)

A. Combination Redemption Payoff Provisions:

Not Applicable

B. Standard Redemption Payoff Provisions:

Applicable

I. Standard Digital/Performance Redemption:

Applicable in accordance with Annex 5, Part B, Chapter 6 Applicable: Specified Dates

The Redemption Payoff applicable to a Redemption Determination Date for Securities for which **Standard Digital/Performance Redemption** is applicable will be calculated on such Redemption Determination Date as follows, expressed as a percentage:

(i) if **Performance_FR** is higher than or equal to **FRB1** on the Redemption Observation Date: As of the date of these Final Terms, indicatively set at 172.50% but may be a lesser or greater amount, provided that it will not be less than 150.00%

(ii) otherwise, if **Performance_FR** is higher than or equal to **FRB2** on the Redemption Observation Date: **100.00%**

(iii) otherwise: **C**

- **FRB1:** 100.00%
- **FRB2 :** 70.00%
- **C:** 80.00%
- **Performance_FR:** **Worst of Performance**, being the result of the following formula, expressed as a percentage:

$$\text{Min}_i^N \text{Performance}(i)$$

- **Performance(i):** Option 1 applies:

$$\frac{\text{Underlying Value}_{2i}}{\text{Underlying Value}_{1i}}$$

- **Redemption Observation Date:** 8 July 2027

i :	Underlying(i):	Underlying Value_{1i}:	Underlying Value_{2i}:	Weight(i)
1	AstraZeneca PLC (with further information set out in paragraph “INFORMATION ON THE UNDERLYING(S) IF ANY”)	Underlying Value on 8 July 2022	Underlying Value on the Redemption Observation Date	Not Applicable
2	Novo Nordisk A/S (with further information set out in paragraph “INFORMATION ON THE UNDERLYING(S) IF ANY”)	Underlying Value on 8 July 2022	Underlying Value on the Redemption Observation Date	Not Applicable
3	Getinge AB (with further information set out in paragraph “INFORMATION ON THE UNDERLYING(S) IF ANY”)	Underlying Value on 8 July 2022	Underlying Value on the Redemption Observation Date	Not Applicable
4	Pfizer Inc (with further information set out in paragraph “INFORMATION ON THE UNDERLYING(S) IF ANY”)	Underlying Value on 8 July 2022	Underlying Value on the Redemption Observation Date	Not Applicable

ii. **Redemption Unwind Costs:** Not Applicable

iii. **Payoff Feature Unwind Costs:** Not Applicable

iv. **Reference Price:** 100%

	(c) Fair Market Value Redemption Amount:	Applicable
	i. Hedge Amount:	Applicable
	ii. Fair Market Value Redemption Amount Percentage:	Not Applicable
	(d) Instalment Redemption Amount determined in accordance with:	Not Applicable
	(e) Physical Settlement:	Not Applicable
	(f) Clean-up Call Option (General Condition 6.7 (<i>Clean-up Call Option</i>)):	Not Applicable
19	Instalment Securities:	Not Applicable
20	Credit Linked Securities:	Not Applicable
21	Bond Linked Securities:	Not Applicable
22	Preference Share Linked Securities:	Not Applicable
23	Linked Redemption Security:	Applicable in accordance with Share Linked Redemption Security (Annex 1) (See paragraph “PROVISIONS RELATING TO THE UNDERLYING(S) IF ANY” for further information in relation to the Underlying(s))

PAYOFF FEATURES (IF ANY) RELATING TO REDEMPTION

24 Payoff Features: Not Applicable

25 PROVISIONS RELATING TO THE UNDERLYING(S) IF ANY

Applicable

Share Linked Security: Share Linked Redemption Security: **Applicable** in accordance with **Annex 1, Chapter 7**

i. Single Underlying: Not Applicable

ii. Basket: **Applicable**

- Basket: i

- Scheduled Trading Day: Scheduled Trading Day (All Shares Basis)

- Exchange Business Day: Exchange Business Day (All Shares Basis)

- Applicable for the purposes of: Standard Redemption Payoff: **Standard Digital/Performance Redemption**

Early Redemption Trigger: **Automatic Early Redemption Event**

Underlying:	Share:	Number of Shares:	Exchange:	Related Exchange:	Valuation Time:	Depository Receipts:	Weighting:
1	AstraZeneca PLC ; ISIN Code: GB0009895292; Bloomberg Ticker: AZN SS	Not Applicable	Stockholm Stock Exchange	All Exchanges	Closing	Not Applicable	Not Applicable

2	Novo Nordisk A/S; ISIN Code: DK0060534915; Bloomberg Ticker: NOVOB DC	Not Applicable	Copenhagen Stock Exchange	All Exchanges	Closing	Not Applicable	Not Applicable
3	Getinge AB ; ISIN Code: SE0000202624; Bloomberg Ticker: GETIB SS	Not Applicable	Stockholm Stock Exchange	All Exchanges	Closing	Not Applicable	Not Applicable
4	Pfizer Inc; ISIN Code: US7170811035; Bloomberg Ticker: PFE UN	Not Applicable	New York Stock Exchange	All Exchanges	Closing	Not Applicable	Not Applicable

- iii. Additional Disruption Event: Applicable in accordance with Share Linked Asset Condition 3.3
- iv. Other Events: Applicable
- v. Maximum Days of Disruption: Eight (8) Scheduled Trading Days
- vi. Payment Extension Days: Two (2) Payment Business Days
- vii. Averaging Date Disruption: Not Applicable
- viii. Observation Date(s): The Initial Observation Date, the Redemption Observation Date and each Early Redemption Observation Date
- ix. Physical Settlement: Not Applicable

PROVISIONS APPLICABLE TO SECURED SECURITIES

- 26 Secured Security Provisions:** Not Applicable

GENERAL PROVISIONS APPLICABLE TO THE SECURITIES

- 27** (a) Form: The Securities are Swedish Securities
- (b) Notes in New Global Note form (NGN Notes) or Certificates in New Global Note form (NGN Certificates): Not Applicable
- (c) CMU Securities: Not Applicable
- 28** Business Day Convention for the purposes of "Payment Business Day" election in accordance with General Condition 5.6 (*Payment Business Day*): Modified Following Payment Business Day
- 29** Additional Financial Centre(s): Stockholm and TARGET2
- 30** Additional Business Centre(s): Not Applicable
- 31** Talons for future Coupons or Receipts to be attached to Definitive Bearer Securities and dates on which such Talons mature: No
- 32** Redenomination (for the purposes of General Condition 3.1): Not Applicable
- 33** (a) Redemption for tax reasons (General Condition 6.3 (*Redemption for tax reasons*)): Not Applicable
- (b) Special Tax Redemption (General: Not Applicable

	Condition 6.4 (<i>Special Tax Redemption</i>):	
(c)	Redemption for FATCA Withholding (General Condition 6.5 (<i>Redemption for FATCA Withholding</i>)):	Applicable
(d)	Regulatory Redemption or Compulsory Resales (General Condition 6.6 (<i>Regulatory Redemption or Compulsory Resales</i>)):	Applicable
(e)	Events of Default (General Condition 10 (<i>Events of Default</i>)):	Applicable
(f)	Illegality and Force Majeure (General Condition 19.1 (<i>Illegality and Force Majeure</i>)):	Applicable
34	Gross Up (General Condition 8.2 (<i>Gross Up</i>)):	Not Applicable
35	Calculation Agent:	Crédit Agricole Corporate and Investment Bank
36	Delivery Agent:	Not Applicable
37	Governing Law:	English law
	Governing Law for the Guarantee:	English law
38	Essential Trigger:	Not Applicable
39	Business Day Convention:	Modified Following Business Day Convention
40	Benchmark Provisions:	Applicable as per the relevant Additional Conditions applicable to the Securities

OPERATIONAL INFORMATION

41	Branch of Account for the purposes of General Condition 5.5 (<i>General provisions applicable to payments</i>):	Not Applicable
----	---	----------------

THIRD PARTY INFORMATION

Not Applicable

Signed on behalf of the Issuer:

DocuSigned by:
Benoit Pélut
4502E88C08D34E5...

Duly authorised

PART B – OTHER INFORMATION

1 LISTING AND ADMISSION TO TRADING

- (a) Listing and admission to trading: Application has been made by the relevant Issuer (or on its behalf) for the Securities to be admitted to trading on NASDAQ OMX Stockholm AB's regulated market with effect from or as soon as practicable on or after the Issue Date and to be listed on the Official List of Nasdaq Stockholm.
- (b) Estimate of total expenses related to admission to trading: See paragraph 4(c) of this Part B

2 RATINGS

Ratings: The Securities to be issued have not been rated

3 INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

Save as discussed in “Subscription and Sale” in the Base Prospectus and save for any fees that may be payable to the Dealer and/or any distributor in connection with the issue of Securities (as the case may be, as described in paragraph 6(d) below), so far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the offer.

4 REASONS FOR THE OFFER AND ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

- (a) Reasons for the offer: The Securities constitute Social Securities and the net proceeds will be used to finance and/or refinance one or more of the Eligible Social Assets described below:
- New or existing eligible social assets (the **Eligible Social Assets**) as further described in the Crédit Agricole Group's social bond framework, as amended and supplemented from time to time (the **Social Bond Framework**), such Securities being referred to as **Social Securities**.
- The Social Bond Framework is based on the Social Bond Principles published by the International Capital Markets Association in its 2020 edition (the **SB Principles**) and is available on the Crédit Agricole Group's website (www.credit-agricole.com/en/finance/finance/debt). The Social Bond Framework may be further updated or expanded to reflect updates to the SB Principles and evolutions in the activities of the Crédit Agricole Group. The Social Bond Framework sets out categories of Eligible Social Assets which have been identified by the Crédit Agricole Group as part of priority activity sectors within the context of sustainable development.
- The Crédit Agricole Group has appointed Vigeo Eiris (**Vigeo**) to provide a second-party opinion (the **Second-Party Opinion**) on the Social Bond Framework, assessing the social added value of the Social Bond Framework and its alignment with the SB Principles.
- This Second-Party Opinion is available on the Crédit

Agricole Group's website (www.credit-agricole.com/en/finance/finance/debt).

The Crédit Agricole Group will publish an annual report on its website detailing the allocation of net income from securities issued by group entities, from which the net proceeds are used to finance and/or refinance new or existing Eligible Social Assets (Crédit Agricole Group Social Securities) and the social impact of the Eligible Social Assets included in its social portfolio. In addition, the Crédit Agricole Group may communicate publicly in the event of substantial changes in the social portfolio. The Crédit Agricole Group will also have an external auditor provide a limited assurance report on the main features of the Crédit Agricole Group Social Securities, for the purposes of the preparation of Crédit Agricole S.A.'s registration document.

- (b) Estimated net proceeds: Issue Price x Aggregate Nominal Amount of the Notes less distribution commissions mentioned in paragraph 6(d) of this Part B
- (c) Estimated total expenses: SEK 25,000 including listing costs and excluding regulatory fees where applicable

5 PERFORMANCE OF UNDERLYING AND OTHER INFORMATION CONCERNING THE UNDERLYING

Underlying: Where past and future performance of the Underlying can be obtained from, free of charge:

Shares:

- AstraZeneca PLC Bloomberg Screen: AZN SS ; ISIN Code: GB0009895292
- Novo Nordisk A/S Bloomberg Screen: NOVOB DC ; ISIN Code: DK0060534915
- Getinge AB Bloomberg Screen: GETIB SS ; ISIN Code: SE0000202624
- Pfizer Inc Bloomberg Screen: PFE UN ; ISIN Code: US7170811035

Post-issuance information

The Issuer does not intend to publish post-issuance information in relation to any underlying element to which the Securities are linked.

6 DISTRIBUTION

- (a) Method of distribution: Non-syndicated
- (b) If syndicated: Not Applicable

- | | |
|--|---|
| (c) If non-syndicated, name and address of Dealer: | Crédit Agricole Corporate and Investment Bank
12, place des États-Unis
CS 70052
92 547 Montrouge Cedex
France |
| (d) Indication of the overall amount of the underwriting commission and of the placing commission: | The Distributor(s) (as defined in paragraph 9 of this Part B) will receive a distribution commission embedded in the Issue Price of the Notes equal to a maximum amount of 1.20 % of the aggregate nominal amount of the Notes. |
| (e) U.S. Selling Restrictions: | For all Securities other than U.S. Securities: to a Permitted Transferee outside the United States in accordance with Regulation S

TEFRA NOT APPLICABLE |
| (f) Prohibition of Sales to EEA Retail Investors: | Not Applicable |
| (g) Prohibition of Sales to UK Retail Investors: | Not Applicable |
| (h) Prohibition of Sales to Belgian Consumers: | Applicable |
| (i) Prohibition of Offer to Private Clients in Switzerland: | Not Applicable |
| (j) U.S. Dividend Equivalent Withholding: | The Securities are not subject to withholding under the Section 871(m) Regulations |

7 OPERATIONAL INFORMATION

- | | |
|--|---|
| (a) ISIN: | SE0015244025 |
| (b) Temporary ISIN: | Not Applicable |
| (c) Common Code: | Not Applicable |
| (d) VALOREN Code: | Not Applicable |
| (e) Other applicable security identification number: | Not Applicable |
| (f) Relevant clearing system(s) other than Euroclear Bank SA/NV and Clearstream Banking, S.A. and the relevant identification number(s): | Swedish CSD: Euroclear Sweden AB, Klarabergsviadukten 63, Box 191, SE-101 23 Stockholm, Sweden |
| (g) Delivery: | Delivery against payment |
| (h) Names and addresses of additional Paying Agent(s) (if any): | Swedish Issuing Agent:
Skandinaviska Enskilda Banken (SEB)
Kungsträdgårdsgatan 8
SE-106 40 Stockholm
Sweden |
| (i) Securities intended to be held in a manner which would allow Eurosystem | No.
Whilst the designation is specified as "no" at the date of |

eligibility:

these Final Terms, should the Eurosystem eligibility criteria be amended in the future such that the Securities are capable of meeting them, the Securities may then be deposited with one of the ICSDs as common safekeeper. Note that this does not necessarily mean that the Securities will then be recognised as eligible collateral for Eurosystem monetary policy and intraday credit operations by the Eurosystem at any time during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.

8 BENCHMARK REGULATION

Benchmark Regulation: Article 29(2) Applicable: Amounts payable under the Securities are calculated by reference to AstraZeneca PLC which is provided by , Novo Nordisk A/S which is provided by , Getinge AB which is provided by and Pfizer Inc which is provided by .

As at the date of these Final Terms, are included in the register of administrators and benchmarks established and maintained by the European Securities and Markets Authority (ESMA) pursuant to article 36 of Regulation (EU) 2016/1011.

9 TERMS AND CONDITIONS OF THE OFFER

- (a) Offer Price: Issue Price
- (b) Conditions to which the offer is subject: The offer of the Notes is conditional on their issue.
- The Issuer reserves the right, in its absolute discretion, to cancel the offer and the issue of the Notes at any time prior to the Issue Date.
- The Issuer shall publish a notice on its website (<http://www.documentation.ca-cib.com/IssuanceProgram>) in the event that the offer is cancelled and the Notes are not issued pursuant to the above.
- For the avoidance of doubt, if any application has been made by a potential investor and the Issuer exercises its right to cancel the offer, such potential investor shall not be entitled to receive any Notes.
- (c) Total amount of the securities offered to the public/admitted to trading; if the amount is not fixed, an indication of the maximum amount of the securities to be offered (if available) and a description of the arrangements and time for announcing to the public the definitive amount of the offer: The total amount of the securities offered to the public is up to SEK 100,000,000.
- The definitive amount of the offer will be published on the website of the Issuer (<http://www.documentation.ca-cib.com/IssuanceProgram>) on or around the Issue Date.
- (d) The time period, including any possible amendments, during which the offer will be open and description of the application process: Prospective investors may apply to subscribe for Notes during the Offer Period.
- The Offer Period may be shortened or extended at any time and for any reason. In such case, the Issuer shall give

notice to the investors as soon as practicable before the end of the Offer Period by means of a notice published on its website (<http://www.documentation.ca-cib.com/IssuanceProgram>).

Applications for the Notes can be made during the Offer Period through the Distributor(s). The applications can be made in accordance with the Distributor(s) usual procedures. Prospective investors will not be required to enter into any contractual arrangements directly with the Issuer or the Dealer related to the subscription for the Notes.

A prospective investor should contact the Distributor(s) prior to the end of the Offer Period. A prospective investor will subscribe for Notes in accordance with the arrangements agreed with the Distributor(s) relating to the subscription of securities generally. There are no pre-identified allotment criteria. The Distributor(s) will adopt allotment criteria that ensure equal treatment of prospective investors. All of the Notes requested through the Distributor(s) during the Offer Period will be as otherwise specified herein.

- | | |
|--|---|
| (e) Description of the possibility to reduce subscriptions and manner for refunding amounts paid in excess by applicants: | Not Applicable.
The Distributor(s), in agreement with the Issuer, reserves the right to accept any subscription requests for Notes which would exceed the Aggregate Nominal Amount of up to SEK 100,000,000 and the Issuer may increase the “up to” Aggregate Nominal Amount.
The Issuer shall publish a notice on its website (http://www.documentation.ca-cib.com/IssuanceProgram) in the event that the “up to” Aggregate Nominal Amount of up to SEK 100,000,000 is exceeded and the “up to” Aggregate Nominal Amount is increased. |
| (f) Details of the minimum and/or maximum amount of the application (whether in number of securities or aggregate amount to invest): | There is no maximum amount of application.
Minimum amount of application is SEK 10,000 |
| (g) Details of the method and time limits for paying up and delivering the Securities: | The Notes will be available on a delivery versus payment basis.
The Notes offered to investors will be issued on the Issue Date against payment by the Distributor(s), via the Dealer, to the Issuer of the gross subscription moneys. Each such investor will be notified by the Distributor(s) of the settlement arrangements in respect of the Notes at the time of such investor's application. |
| (h) A full description of the manner in and date on which results of the offer are to be made public: | Publication on the website of the Issuer (http://www.documentation.ca-cib.com/IssuanceProgram) on or around the Issue Date. |
| (i) Procedure for exercise of any right of pre-emption, negotiability of subscription rights | Not Applicable |

and treatment of subscription rights not exercised:

- | | | |
|-----|---|---|
| (j) | The various categories of potential investors to which the securities are offered: | The Notes are offered to the public to eligible counterparties, professional client and retail Investors |
| (k) | Whether a tranche has been or is being reserved for certain countries, indicate any such tranche: | Not Applicable |
| (l) | Process for notifying applicants of the amount allotted and an indication whether dealing may begin before notification is made: | Applicants will be notified directly by the Distributor(s) of the success of their application. Dealing in the Notes may commence on the Issue Date. |
| (m) | Indication of the amount of any expenses and taxes charged to the subscriber or purchaser: | See paragraph 6(d) above.

Responsibility for any tax implications of investing in these Notes rests entirely with the subscriber or purchaser. |
| (n) | In the case of admission to trading on a regulated market, the name and address of the entities which have a firm commitment to act as intermediaries in secondary trading, providing liquidity through bid and offer rates and description of the main terms of their commitments: | Not Applicable |
| (o) | Non-Exempt Offer Consent of the Issuer to use the Base Prospectus during the Offer Period: | Applicable. An offer of the Securities may be made by the Dealers and Garantum Fondkommission AB Norrmalmstorg, Smålandsgatan (the Initial Authorised Offeror) and any additional financial intermediaries who have obtained or obtain the Issuer's specific consent to use the Base Prospectus in connection with the Non-exempt Offer and who are identified on the website at http://www.documentation.ca-cib.com/IssuanceProgram (the Additional Authorised Offeror) and each additional financial intermediaries who has accepted the Issuer's offer of general consent to use the Base Prospectus in connection with the Non-exempt Offer by publishing on such additional financial intermediary's website or the website of Initial Authorised Offeror (if any) that it is using the Base Prospectus for such Non-exempt Offer in accordance with the general consent of the Issuer (the General Authorised Offer) (together, the Authorised Offerors) other than pursuant to Articles 1(4) and/or 3(2) of the Prospectus Regulation in (the Non-Exempt Offer Jurisdiction) during the period from 24 May 2022 until 30 June 2022 (the Offer Period). |
| (p) | Conditions attached to the consent of the relevant Issuer to use the Base Prospectus: | Specific Consent and General Consent |
| (q) | Authorised Offeror(s): | Garantum Fondkommission AB Norrmalmstorg, Smålandsgatan |

16 P.O. Box 7364, 103 90 Stockholm, Sweden

(the **Initial Authorised Offeror**)

and

Any Additional Authorised Offeror

and

Any General Authorised Offeror.

(r) Other conditions to consent:

Not Applicable

10 REPRESENTATION OF HOLDERS

Not Applicable

ANNEX A – ISSUE SPECIFIC SUMMARY

1. INTRODUCTION AND DISCLAIMERS

Crédit Agricole CIB Financial Solutions (**Crédit Agricole CIB FS** or the **Issuer**) is a limited liability company with a board of directors whose registered office is located at 12, place des États-Unis, CS 70052, 92 547 Montrouge Cedex, France. The Legal Entity Identifier (LEI) of the Issuer is: 969500HUHIE5GG515X42.

The debt securities (the **Notes**) issued by the Issuer are structured notes whose return depends on the performance of a share included in a basket of shares. The Notes are identified by the ISIN Code SE0015244025.

This document constitutes the Summary to the Prospectus (the **Summary**) for the purpose of Regulation (EU) 2017/1129 (the **Prospectus Regulation**) and must be read in conjunction with:

- the base prospectus approved on 10 May 2022 by the CSSF in Luxembourg, 283 route d'Arlon L-1150 Luxembourg, email: direction@cssf.lu, as competent authority under the Prospectus Regulations (the **Base Prospectus**), completed by
- the Final Terms dated 24 May 2022 (the **Final Terms**),

which together constitute a prospectus for the purposes of the Prospectus Regulation containing the necessary information concerning the issuer and the securities offered to the public or to be admitted to trading on a regulated market (the **Prospectus**).

Full information on the Issuer, the Guarantor if any, and the offer of the Notes is only available on the basis of the combination of the Base Prospectus and the Final Terms.

Warning to the reader

This summary should be read as an introduction to the Prospectus. Any decision to invest in the Notes should be based on a thorough review of the Prospectus as a whole, including the Base Prospectus, any documents incorporated by reference thereto, any supplement from time to time and the Final Terms, by the investor.

An investor may lose all or part of the capital invested in the Notes issued by the Issuer. Where an action relating to the information contained in the Prospectus is brought before a court, the plaintiff investor may, under national law, be required to bear the costs of translation of the Prospectus before the commencement of the legal proceedings.

Civil liability will only be sought from the persons who filed the Summary, including any translation thereof, but only if the contents of the Summary are found to be misleading, inaccurate or inconsistent when read together with other parts of the Prospectus or if it does not provide, when read together with the other parts of the Prospectus, key information to assist investors when considering investing in such Notes.

You are about to buy a product that is not simple and can be difficult to understand.

2. KEY INFORMATION ABOUT THE ISSUER

2.1 Who is the issuer of the securities?

Crédit Agricole CIB FS is limited liability company incorporated on 30 December 2003 under the laws of the Republic of France as a “*société anonyme*” governed by a board of directors registered at the *Registre du Commerce et des Sociétés de Nanterre* under the reference SIRET 45142804900014 and having its registered office is located at 12, place des États-Unis, CS 70052, 92 547 Montrouge Cedex, France. Its legal entity identifier (LEI) is 969500HUHIE5GG515X42.

A. Principal activities

Crédit Agricole CIB FS pursues the activity of issuing debt securities.

B. Organisational Structure / Major shareholders

Crédit Agricole Corporate and Investment Bank (**Crédit Agricole CIB**) and its consolidated subsidiaries taken as a whole (the **Crédit Agricole Group**) includes Crédit Agricole CIB FS, which is a consolidated subsidiary of Crédit Agricole CIB. Crédit Agricole CIB FS has no subsidiaries. Crédit Agricole CIB, *société anonyme* incorporated in France, is the immediate parent company of Crédit Agricole CIB FS with a 99.80 per cent shares and therefore controls Crédit Agricole CIB FS.

C. Key executives

The Chairman and Chief Executive Officer of the Issuer is Christine CREMEL.

D. Statutory Auditors

The statutory auditor of Crédit Agricole CIB FS is PricewaterhouseCoopers Audit, 63 rue de Villiers, 92200 Neuilly sur Seine, France, which is a member of the *Compagnie régionale des commissaires aux comptes de Versailles*.

The deputy statutory auditor of the Issuer is Jean-Baptiste Deschryver, 63 rue de Villiers, 92200 Neuilly sur Seine, France which is a member of the *Compagnie régionale des commissaires aux comptes de Versailles*.

2.2 What is the key financial information concerning the Issuer?

The following tables show selected key financial information (within the meaning of Delegated Regulation (EU) 2019/979) of the Issuer for the financial years ended 31 December 2020 and 31 December 2021 (all figures are expressed in euros):

A. Income Statement

	30/06/2020	31/12/2020 (audited)	30/06/2021	31/12/2021 (audited)
Operating profit/loss or another similar measure of financial performance used by the issuer in the financial statements	221,824	143,588	26,414	74,031

B. Balance sheet for non-equity securities

	30/06/2020	31/12/2020 (audited)	30/06/2021	31/12/2021 (audited)
Net financial debt (long term debt plus short term debt minus cash)	7,160,158,628	7,044,739,604	7,594,378,822	7,272,910,432
Current ratio (current assets/current liabilities)	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Debt to equity ratio (total liabilities/total shareholder equity)	36,046	34,934	37,769	35,335
Interest cover ratio (operating income/interest expense)	Not Applicable	Not Applicable	Not Applicable	Not Applicable

C. Cash flow statement for non-equity securities

	30/06/2020	2020 (audited)	30/06/2021	31/12/2021 (audited)
Net Cash flows from operating	82,942,305	200,313,809	(549,326,624)	(228,578,420)
Net Cash flows from financing	(85,537,094)	(200,956,117)	549,639,218	228,170,827
Net Cash flow from investing	Not Applicable	Not Applicable	Not Applicable	Not Applicable

D. Qualifications in the audit report

The audit reports do not contain any qualifications with respect to Crédit Agricole CIB FS' historical financial information.

2.3 What are the issuer's specific risks?

The following risks have been identified as being significant and specific to the Issuer and of a nature, should they materialise, to have a significant negative impact on its business activity, its financial position and its access to various sources of financing:

1) Crédit Agricole CIB FS could suffer losses if a resolution procedure were to be initiated or if the Crédit Agricole Group's financial situation were to deteriorate significantly; and

2) Crédit Agricole CIB FS is highly dependent on Crédit Agricole CIB, its parent company. In addition, Crédit Agricole CIB FS bears a credit risk on Crédit Agricole CIB which is the sole counterparty for Crédit Agricole CIB FS' financial transactions.

3. KEY INFORMATION ON THE SECURITIES

3.1 What are the main characteristics of securities?

A. General

The Notes to be issued by the Issuer are structured notes whose return depends on the performance of a share included in a basket of shares (each, an **Underlying** indexed "i"). Information on the past and future performance of each Underlying(i) will be published on Bloomberg (Bloomberg Ticker : AZN SS for AstraZeneca PLC, Bloomberg Ticker : NOVOB DC for Novo Nordisk A/S, Bloomberg Ticker : GETIB SS for Getinge AB and Bloomberg Ticker : PFE UN for Pfizer Inc). The Notes will only be identified by the ISIN Code SE0015244025.

The Notes are denominated in Swedish Kronor (**SEK**; also the **Specified Currency**) and any redemption amount payable will be in the Specified Currency.

The maximum nominal amount of the Notes offered is up to SEK 100,000,000, represented by 10,000 Notes with a notional amount of SEK 10,000 each (the **Notional Amount**). The issue price is 100.00% of the aggregate nominal amount of the Notes.

The Minimum Trade is not applicable.

The Notes will be issued on 27 July 2022 (the **Issue Date**) in uncertificated and dematerialised book-entry form.

The maturity date of the Notes will be 22 July 2027 (the **Maturity Date**).

The Notes are governed by English law.

B. Ratings

Not applicable, the Notes have not been rated.

C. Description of the rights, ranking and restrictions attached to the Notes

Ranking: the Notes constitute direct, unsubordinated and guaranteed obligations of the Issuer and rank and will rank *pari passu* among themselves and (subject to certain exceptions established by law) equally with all other unsecured obligations (other than subordinated obligations, if any) of the Issuer, present or future.

Early Redemption Events: the terms and conditions of the Notes provide for events triggering the early redemption of the Notes. The Notes will become due and payable upon notice to Investors following the occurrence of any such early redemption event.

Substitution: Crédit Agricole S.A. may be substituted by Crédit Agricole CIB as Guarantor with respect to the Notes, upon the joint decision of Crédit Agricole S.A. and Crédit Agricole CIB, without the consent of the holders of the Notes (the **Noteholders**).

D. Interest

No periodic coupon is paid on the Notes.

E. Redemption

Automatic Early Redemption:

Provided that on any **Early Redemption Observation Date** specified in the table below, the **Worst of Performance** is greater than or equal to the relevant **Early Redemption Barrier** (or **ERB**, as specified in the table below) (an **Automatic Early Redemption Event**), the investor will receive on the immediately following **Early Redemption Date** specified in the table below a cash settlement amount per Note in the Specified Currency equal to the following Automatic Early Redemption Amount: **Notional Amount** x **Reference Price**

Where:

Reference Price means, in relation to the relevant Early Redemption Observation Date, the corresponding Reference Price specified in the table below;

Worst of Performance means the result of the following formula, expressed as a percentage:

$$\text{Min}_i^N \text{Performance}(i)$$

With,

N means the total number of Underlyings(i);

Performance(i) means, in respect of each Underlying(i) comprising the Basket, the result of the following formula, expressed as a percentage:

$$\frac{\text{Underlying Value}_{e_i}}{\text{Underlying Value}_{i1}}$$

Underlying Value_{e_i} means the relevant Underlying Value on the relevant Early Redemption Observation Date;

Underlying Value_{i1} means the relevant Underlying Value on 8 July 2022 (the **Initial Observation Date**);

Underlying Value means the closing price of the relevant Underlying(i) on the Initial Observation Date or relevant Early Redemption Observation Date, as the case may be; and

Basket means:

i	Underlying	Underlying Value _{i1}
	AstraZeneca PLC	-
	Novo Nordisk A/S	-
	Getinge AB	-
	Pfizer Inc	-

t	Early Redemption Observation Date	Early Redemption Date	ERB	Reference Price
1	10/07/2023	24/07/2023	100%	Indicatively set at 114.50% but may be a lesser or greater amount, provided that it will not be less than 110.00%
2	08/07/2024	22/07/2024	100%	Indicatively set at 129.00% but may be a lesser or greater amount, provided that it will not be less than 120.00%
3	08/07/2025	22/07/2025	100%	Indicatively set at 143.50% but may be a lesser or greater amount, provided that it will not be less than 130.00%
4	08/07/2026	22/07/2026	100%	Indicatively set at 158.00% but may be a lesser or greater amount, provided that it will not be less than 140.00%

Final Redemption:

Provided that the Notes have not been early redeemed, the Notes will be redeemed on the Maturity Date. The investor will receive a cash settlement amount per Note in the Specified Currency equal to the following Final Redemption Amount:

Notional Amount x (Reference Price x Redemption Payoff)

Where:

Reference Price means 100%, and

Redemption Payoff will be calculated as follows:

(i) if **Performance_FR** is higher than or equal to **FRB1** on the Redemption Observation Date: indicatively set at 172.50% but may be a lesser or greater amount, provided that it will not be less than 150.00%

(ii) otherwise, if **Performance_FR** is higher than or equal to **FRB2** on the Redemption Observation Date: **100.00%**

(iii) otherwise: **C**

With:

FRB1 means 100.00%

FRB2 means 70.00%

C means 80.00%

Performance_FR means Worst of Performance; and

Worst of Performance means the result of the following formula, expressed as a percentage:

$$\text{Min}_i^N \text{Performance}(i)$$

With:

N means the total number of Underlyings(i);

Performance(i) means, in respect of each Underlying(i) comprising the Basket, the result of the following formula, expressed as a percentage:

$$\frac{\text{Underlying Value}_{2i}}{\text{Underlying Value}_{1i}}$$

Underlying Value_{2i} means the relevant Underlying Value on 8 July 2027 (the **Redemption Observation Date**);

Underlying Value_{1i} means the relevant Underlying Value on the Initial Observation Date;

Underlying Value means the closing price of the relevant Underlying(i) on the Initial Observation Date or the Redemption Observation Date, as the case may be; and

Basket means:

i	Underlying	Underlying Value _{1i}
	AstraZeneca PLC	-
	Novo Nordisk A/S	-
	Getinge AB	-
	Pfizer Inc	-

Other redemption events:

During the life of the Notes, they may also be redeemed at their fair market value:

- at the hand of the Issuer, following an event of illegality or an event of force majeure or for regulatory or compulsory resales; or
- at the hand of the holders, in the event of an event of default or a tax change giving rise to a withholding tax case and in the event of a FATCA withholding tax case.

The Issuer may at any time redeem Notes on or off the stock exchange at any price agreed with the seller(s), subject to applicable laws and regulations.

3.2 Where will the securities be traded?

The Notes are expected to be admitted to trading on or as soon as practicable after the Issue Date, on NASDAQ OMX Stockholm AB's regulated market, a regulated market within the meaning of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014, as amended, and to be listed on the Official List of Nasdaq Stockholm.

3.3 Are the securities covered by a guarantee?

The issue of the Notes is subject to an independent first demand guarantee granted by Crédit Agricole CIB (the **Guarantor**) in respect of any amount that may be claimed by the holders in respect of the Notes (the **Guarantee**).

The Guarantor is the immediate parent company of the Issuer, in which it holds a 99.80% interest and consequently controls the Issuer. Crédit Agricole CIB's legal entity identifier (LEI) is 1VUV7VQFKUOQSJ21A208.

The following tables show selected key financial information (within the meaning of Delegated Regulation (EU) 2019/979) of the Guarantor for the financial years ending 31 December 2020 and 31 December 2021 (all figures are expressed in millions of euros):

A. Income statement for credit institutions

	30/06/2020	31/12/2020 (audited)	30/06/2021	31/12/2021 (audited)
Net interest income (or equivalent)	1,479	3,182	1,631	3,377
Net fee and commission income	494	939	424	941
Net impairment loss on financial assets	-	-	-	-
Net trading income	1,067	1,738	903	1,501
Measure of financial performance used by the issuer in the financial statements such as operating profit	1,223	2,435	1,044	2,218
Net profit or loss (for consolidated financial statements net profit or loss attributable to equity holders of the parent) ie. Net income Group share	672	1,341	789	1,691

B. Balance sheet for credit institutions

	30/06/2020	31/12/2020 (audited)	30/06/2021	31/12/2021 (audited)	Value as outcome from the most recent Supervisory Review and Evaluation Process ('SREP') (unaudited)
Total assets	631,396	593,890	595,835	599,721	Not Applicable
Senior debt	51,858	42,229	46,609	51,768	Not Applicable
Subordinated debt	4,518	4,351	4,188	4,079	Not Applicable
Loans and receivables from customers (net)	153,339	142,000	147,385	165,830	Not Applicable
Deposits from customers	153,449	149,084	150,356	159,578	Not Applicable
Total equity	22,983	22,606	25,534	26,520	Not Applicable
Non performing loans (based on gross carrying amount)/Loans and receivables)	2.1%	2.2%	2.1%	1.8%	Not Applicable
Phased-in Common Equity Tier 1 capital (CET1) ratio or other relevant prudential capital adequacy ratio depending on the issuance	10.9%	11.7%	11.2%	11.7%	7.9%
Phased-in Total Capital Ratio	18.2%	19.2%	20.6%	21.0%	12.0%
Leverage Ratio calculated under applicable regulatory framework	3.3%	3.5%	3.7%	4.0%	Not Applicable

C. Qualifications in the audit report

The audit reports do not contain any qualifications with respect to Crédit Agricole CIB's historical financial information.

D. Principal risk factors related to the guarantor

Crédit Agricole CIB is mainly exposed to the following categories of risks in the conduct of its business:

- 1) Credit and counterparty risks, which include the Guarantor's credit risk, the Guarantor's counterparty risk in connection with its market activities or the Guarantor's credit risk in connection with its securitization transactions on behalf of clients;
- 2) Financial risks, which include liquidity risk, market risk, foreign exchange risk, risk of holding equities, issuer's risk and global interest rate risk; and
- 3) Operational risks and associated risks, which include fraud, human resource risks, legal and reputational risks, compliance risks, tax risks, information systems risks, providing of inappropriate financial services (conduct risk), risks of failure of business processes including credit processes, or the use of a model (model risk), as well as potential financial consequences related to the management of reputational risk.

3.4 What are the main risks specific to securities?

There are risk factors which are material for the purpose of assessing the risks related to the Notes, including the following:

- 1) The trading price of the Notes may fall in value as rapidly as it may rise and Noteholders may sustain a total loss of their investment;
- 2) The Notes may have no established trading market when issued, and one may never develop. If a market does develop, it may not be very liquid. Illiquidity may have an adverse effect on the market value of the Notes;
- 3) The implementation in France of the EU Bank Recovery and Resolution Directive could materially affect the rights of the Noteholders, the price or value of their investment in the Notes and or the ability of the Guarantor to satisfy its obligations under the Notes;
- 4) French insolvency law could have an adverse impact on Noteholders seeking repayment in the event that the Issuer, the Guarantor or its subsidiaries were to become insolvent and could have a material adverse effect on the market value of the Notes;
- 5) The risk relating to the unsecured nature of the Notes and the Guarantee, the absence of negative pledge and debt restrictions with respect to the Issuer and the Guarantor, all of which could have an adverse effect on the market value of the Notes;
- 6) The optional redemption feature of the Notes might negatively affect the market value of the Notes. The Noteholders may not receive the total amount of the capital invested;
- 7) The Automatic Early Redemption Amount and the Final Redemption Amount of the Notes are dependent upon changes in the market value of the Underlying(s), which could adversely affect the market value of the Notes. In addition, the Early Redemption Amount and the Final Redemption Amount may be less than the nominal amount of the Notes and the holders of Notes may lose all or part of the amount of the principal invested;
- 8) An investment in the Notes does not confer any legal or beneficial interest in the Underlying(s) or any voting rights, right to receive dividends or other rights that a holder of the Underlying(s) may have. Potential losses in value of the Notes cannot be compensated by other income; and
- 9) The Notes are not principal protected and investors are exposed to the performance of the Underlying(s); accordingly, they risk losing all or a part of their investment if the value of the Underlying(s) does not move in a positive direction.

4. KEY INFORMATION ON THE PUBLIC OFFER OF SECURITIES AND/OR ADMISSION TO TRADING ON A REGULATED MARKET

4.1 Under what conditions and according to what timetable can I invest in this security?

The Notes are offered for a maximum amount of SEK 100,000,000.

The Notes are expected to be admitted to trading on or as soon as practicable after the Issue Date, on NASDAQ OMX Stockholm AB's regulated market, a regulated market within the meaning of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014, as amended, and to be listed on the Official List of Nasdaq Stockholm.

The Notes will be offered to eligible counterparties, professional client and/or retail Investors, during an open period from 24 May 2022 to 30 June 2022 (the **Offer Period**) in Sweden, subject to (i) the Notes being admitted to trading, if applicable, and (ii) an early closure of the Offer Period in the Issuer's sole and absolute discretion depending on market conditions, as specified below.

Prospective investors may apply to subscribe for Notes during the Offer Period. The Offer Period may be shortened or extended at any time and for any reason. In such case, the Issuer shall give notice to the investors as soon as practicable before the end of the Offer Period by means of a notice published on its website (<http://www.documentation.ca-cib.com/IssuanceProgram>).

Applications for the Notes can be made during the Offer Period through the Distributor (as defined below). The applications can be made in accordance with the Distributor's usual procedures. Prospective investors will not be required to enter into any contractual arrangements directly with the Issuer or the Dealer (as defined below) related to the subscription for the Notes.

A prospective investor will subscribe for Notes in accordance with the arrangements agreed with the Distributor relating to the subscription of securities generally.

The Notes will be available on a delivery versus payment basis. The Notes offered to investors will be issued on the Issue Date against payment by the Distributor, via the Dealer, to the Issuer of the gross subscription moneys. Each such investor will be notified by the Distributor of the settlement arrangements in respect of the Notes at the time of such investor's application.

The Issuer estimates that the Notes will be delivered to the investor's respective book-entry securities account on or around the Issue Date. Applicants will be notified directly by the Distributor of the success of their application. Dealing in the Notes may commence on the Issue Date.

If the subscription for a Note occurs after the closing of the offering, the order will be automatically cancelled and the subscription proceeds will be returned to the relevant investor in accordance with the instructions communicated to Crédit Agricole CIB at the time of the subscription request. Subscription requests for Notes will be received within the limit of the number of Notes available. Subscription orders for Notes may be reduced in the event of oversubscription and any excess proceeds will be returned by Crédit Agricole CIB to the investor. Each Distributor (as defined below) will be paid aggregate commissions equal to a maximum of 1.20% of the aggregate nominal amount of the Notes.

There is no pre-emptive right to subscribe the Notes for the benefit of any category of persons.

The final amount of the offering will be notified by the Issuer to each investor via its website (<https://www.documentation.ca-cib.com/IssuanceProgram>) on or around the Issue Date.

Estimate of the total expenses: SEK 25,000, including listing costs and excluding regulatory fees where applicable.

No expenses will be charged to the investors.

4.2 Who is the offeror and/or the person asking for admission to trading?

(i) Crédit Agricole CIB (the **Dealer**) and (ii) Garantum Fondkommission AB Norrmalmstorg, Smålandsgatan (the **Distributor**), and (iii) any additional financial intermediary appointed by the Issuer and as identified on the website at <https://www.documentation.ca-cib.com/PublicFinalTerm?region=EU> and (iv) any financial intermediaries stating on its website that it uses the prospectus in accordance with the conditions set out under "Retail Cascades" in the Base Prospectus may offer the Notes.

4.3 Why is the Prospectus being prepared?

A. Net Proceeds and Use of Proceeds:

The estimated net proceeds from the issue of the Notes of up to SEK 100,000,000 will be used to finance and/or refinance in whole or in part, new or existing eligible social assets (the Eligible Social Assets), as further described in the Social Bond Framework available on Credit Agricole Group's website ([/www.credit-agricole.com/en/finance/finance/debt](http://www.credit-agricole.com/en/finance/finance/debt)).

A. Subscription Agreement:

Not applicable - the offer is not the subject of a subscription agreement.

B. Conflicts of interest:

The Guarantor is also the calculation agent; as a result, conflicts of interest may exist between the calculation agent and the holders of Notes, in particular with respect to certain determinations and determinations that the calculation agent may make pursuant to the Terms and which may affect amounts due under the Notes.